

# Vikas P Sukhatme

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3269630/vikas-p-sukhatme-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

7,104  
citations

32  
h-index

44  
g-index

44  
ext. papers

7,983  
ext. citations

10  
avg, IF

5.1  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 43 | Visualizing the effects of lactate dehydrogenase (LDH) inhibition and LDH-A genetic ablation in breast and lung cancer with hyperpolarized pyruvate NMR. <i>NMR in Biomedicine</i> , <b>2021</b> , 34, e4560                              | 4.4  | 4         |
| 42 | Aspirin-triggered proresolving mediators stimulate resolution in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 6292-6297  | 11.5 | 74        |
| 41 | Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. <i>FASEB Journal</i> , <b>2019</b> , 33, 114-125  | 0.9  | 24        |
| 40 | Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 2964-2979  | 15.9 | 50        |
| 39 | Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 1698-1703 | 11.5 | 59        |
| 38 | Resolvins suppress tumor growth and enhance cancer therapy. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 115-140  | 16.6 | 142       |
| 37 | Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1 $\alpha$ and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. <i>Journal of Cellular Physiology</i> , <b>2017</b> , 232, 192-201                      | 7    | 16        |
| 36 | Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2017</b> , 27, 929-935                                  | 2.9  | 5         |
| 35 | Adipose-derived aldehyde dehydrogenase-expressing cells promote dermal regenerative potential with collagen-glycosaminoglycan scaffold. <i>Wound Repair and Regeneration</i> , <b>2017</b> , 25, 109-119                                  | 3.6  | 11        |
| 34 | Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase. <i>European Journal of Medicinal Chemistry</i> , <b>2017</b> , 126, 920-928  | 6.8  | 42        |
| 33 | Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway. <i>Scientific Reports</i> , <b>2017</b> , 7, 4537   | 4.9  | 61        |
| 32 | Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 11756-69   | 3.3  | 83        |
| 31 | Selective spectroscopic imaging of hyperpolarized pyruvate and its metabolites using a single-echo variable phase advance method in balanced SSFP. <i>Magnetic Resonance in Medicine</i> , <b>2016</b> , 76, 1102-15                      | 4.4  | 16        |
| 30 | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea. <i>Cureus</i> , <b>2015</b> , 7, e441                                    | 1.2  | 3         |
| 29 | Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. <i>Cell Metabolism</i> , <b>2014</b> , 19, 795-809                                     | 24.6 | 311       |
| 28 | Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling. <i>Scientific Reports</i> , <b>2014</b> , 4, 5414   | 4.9  | 55        |
| 27 | Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. <i>Journal of Immunology</i> , <b>2013</b> , 191, 1486-95  | 5.3  | 380       |

|    |  |      |     |
|----|--|------|-----|
| 26 | Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology. <i>OncImmunology</i> , <b>2013</b> , 2, e26383  | 7.2  | 60  |
| 25 | Modeling precision treatment of breast cancer. <i>Genome Biology</i> , <b>2013</b> , 14, R110  | 18.3 | 204 |
| 24 | Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. <i>Journal of Cellular Physiology</i> , <b>2012</b> , 227, 1709-20 | 7    | 106 |
| 23 | Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence. <i>FEBS Letters</i> , <b>2012</b> , 586, 2389-95   | 3.8  | 51  |
| 22 | Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. <i>PLoS ONE</i> , <b>2010</b> , 5, e12520  | 3.7  | 38  |
| 21 | A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. <i>Cancer</i> , <b>2010</b> , 116, 1751-6  | 6.4  | 60  |
| 20 | Repurposing for Neglected Diseases--Response. <i>Science</i> , <b>2009</b> , 326, 935-935  | 33.3 |     |
| 19 | Targeting tumor vascular endothelium: an emerging concept for cancer therapy. <i>Drug Development Research</i> , <b>2008</b> , 69, 340-351   | 5.1  | 1   |
| 18 | The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 3940-51  | 15.9 | 186 |
| 17 | Biomarkers for monitoring antiangiogenic therapy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 777s-780s  | 12.9 | 26  |
| 16 | A critical role for calponin 2 in vascular development. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 6664-725.4   | 47   |     |
| 15 | A novel endothelial-specific heat shock protein HspA12B is required in both zebrafish development and endothelial functions in vitro. <i>Journal of Cell Science</i> , <b>2006</b> , 119, 4117-26  | 5.3  | 52  |
| 14 | Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. <i>PLoS Medicine</i> , <b>2006</b> , 3, e46   | 11.6 | 373 |
| 13 | Magic roundabout, a tumor endothelial marker: expression and signaling. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 332, 533-41   | 3.4  | 101 |
| 12 | Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 490-8  | 7.5  | 73  |
| 11 | Critical roles of CD146 in zebrafish vascular development. <i>Developmental Dynamics</i> , <b>2005</b> , 232, 232-44   | 2.9  | 37  |
| 10 | Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 13641-7   | 5.4  | 91  |
| 9  | Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. <i>FASEB Journal</i> , <b>2005</b> , 19, 270-1  | 0.9  | 54  |

|   |  |      |      |
|---|--|------|------|
| 8 | Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 649-58 | 15.9 | 2717 |
| 7 | In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 388-99  | 9.7  | 50   |
| 6 | Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. <i>American Journal of Physiology - Cell Physiology</i> , <b>2001</b> , 280, C1140-50                       | 5.4  | 41   |
| 5 | Activation of vitamin D receptor by the WilmsTumor gene product mediates apoptosis of renal cells. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 1188-1196                                | 12.7 | 45   |
| 4 | Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. <i>Nature</i> , <b>2000</b> , 408, 990-4   | 50.4 | 679  |
| 3 | Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. <i>Oncogene</i> , <b>1999</b> , 18, 1205-8  | 9.2  | 101  |
| 2 | Combined effects of angiostatin and ionizing radiation in antitumour therapy. <i>Nature</i> , <b>1998</b> , 394, 287-91  | 50.4 | 570  |
| 1 | Tumor size does not limit radiation-inducible gene therapy in a human xenograft model. <i>Radiation Oncology Investigations</i> , <b>1995</b> , 3, 238-242   |      | 2    |